BioNTech SE (NASDAQ: BNTX) is 14.93% higher on its value in year-to-date trading and has touched a low of $28.00 and a high of $131.00 in the current 52-week trading range. The BNTX stock was last observed hovering at around $93.69 in the last trading session, with the day’s gains setting it 5.17% off its average median price target of $97.88 for the next 12 months. It is also 10.76% off the consensus price target high of $110.78 offered by 11 analysts, but current levels are -34.91% lower than the price target low of $73.28 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $98.86, the stock is -2.06% and -2.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.86 million and changing 5.52% at the moment leaves the stock 34.91% off its SMA200. BNTX registered 107.74% gain for a year compared to 6-month gain of 42.80%. The firm has a 50-day simple moving average (SMA 50) of $105.85 and a 200-day simple moving average (SMA200) of $83.82.
The stock witnessed a -25.47% loss in the last 1 month and extending the period to 3 months gives it a 8.65%, and is 11.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.47% over the week and 7.13% over the month.
Fwd P/E is 5.75. Distance from 52-week low is 253.07% and -24.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.40%).
BioNTech SE (BNTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for BioNTech SE (BNTX) is a “Overweight”. 11 analysts offering their recommendations for the stock have an average rating of 2.40, where 5 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
BioNTech SE is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at $0.18 with sales reaching $353.32M over the same period.The EPS is expected to shrink by -300.50% this year, but quarterly earnings will post 447.30% year-over-year. Quarterly sales are estimated to grow 1,034.60% in year-over-year returns.
BioNTech SE (BNTX) Top Institutional Holders
207 institutions hold shares in BioNTech SE (BNTX), with 2.85M shares held by insiders accounting for 1.18% while institutional investors hold 10.64% of the company’s shares. The shares outstanding are 238.67M, and float is at 223.06M with Short Float at 2.84%. Institutions hold 10.51% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 4.5 million shares valued at $311.73 million. The investor’s holdings represent 34.11% of the BNTX Shares outstanding. As of Sep 29, 2020, the second largest holder is Primecap Management Company with 4.13 million shares valued at $285.62 million to account for 31.25% of the shares outstanding. The other top investors are Artisan Partners Limited Partnership which holds 1.78 million shares representing 13.48% and valued at over $123.21 million, while Artal Group S.A. holds 13.12% of the shares totaling 1.73 million with a market value of $119.85 million.